SAN DIEGO, Oct. 26 /PRNewswire-FirstCall/ -- Nanogen, Inc. (Nasdaq: NGEN)
will host a conference call on Wednesday, November 3, 2004 at 4:30 p.m.
Eastern (1:30 p.m. Pacific) to discuss 2004 third quarter financial results.
The financial results press release will be issued at close of market on
Audio of management's presentation will be available via live webcast on
the investor relations section of Nanogen's corporate website at
www.nanogen.com, and will be archived for 90 days. A digital recording of the
call will also be available for 48 hours, beginning two hours after the
completion of the conference call on November 3, and can be accessed via
telephone at (877) 519-4471 for US/Canada participants, and (973) 341-3080 for
international participants. The conference ID, 5299122, will be required to
listen to the playback.
About Nanogen, Inc.
Nanogen develops advanced in vitro diagnostics to provide physicians and
patients worldwide with sophisticated information to predict, diagnose and
treat disease. Research and clinical reference labs use the highly accurate
and reliable NanoChip(R) Molecular Biology Workstation and NanoChip(R)
Electronic Microarray to develop tests to detect genetic mutations associated
with a variety of diseases, such as cystic fibrosis, Alzheimer's and
cardiovascular disease. Nanogen's subsidiary SynX offers a line of
point-of-care antibody-based diagnostic tests and is building expertise in
cardiac related health conditions. Nanogen's ten years of pioneering research
involving nanotechnology may also have future applications in medical
diagnostics, biowarfare and other industries. For additional information
please visit Nanogen's website at www.nanogen.com.
This press release contains forward-looking statements that are subject to
risks and uncertainties that could cause actual results to differ materially
from those set forth in the forward-looking statements, including whether
patents owned or licensed by Nanogen will be developed into products, whether
the patents owned by Nanogen offer any protection against competitors with
competing technologies, whether Nanogen's NanoChip(R) System can be
successfully further commercialized, whether other products under development
can be successfully developed and commercialized, whether results reported by
our customers or partners can be identically replicated, whether ASRs
currently sold by Nanogen will become FDA-approved molecular diagnostic test
kits, whether Nanogen will be successful in developing additional ASRs and
protocols utilizing the NanoChip(R) System, and other risks and uncertainties
discussed under the caption "Factors That May Affect Results" and elsewhere in
Nanogen's Form 10-K or Form 10-Q most recently filed with the Securities and
Exchange Commission. These forward-looking statements speak only as of the
date hereof. Nanogen disclaims any intent or obligation to update these
SOURCE Nanogen, Inc.